Articles from Tasso, Inc.

Tokyo & Kagoshima, Japan (March 28, 2025 JST) / Seattle, Washington, USA (March 27, 2025 PT): Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Representative Chairman, President & CEO: Ryoichi Nagata, M.D., Ph.D.; hereinafter “SNBL”) and Tasso, Inc., the Seattle-based leading provider of patient-centric, clinical grade blood collection solutions (Co-founder & CEO: Ben Casavant, Ph.D.; hereinafter “Tasso”) hereby announce that they have agreed to establish a new joint venture company (hereinafter “JV”) for exclusive distribution of Tasso’s proprietary on-demand blood collection device in Japan.

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing.

InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021. In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso blood collection solutions for the anti-doping marketplace.

Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program. The new offering expands the foundation and expertise of the Tasso Care services platform in remote blood collection and analysis to support clinical trial recruitment.

Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, today announced it received CE Mark certification for its Tasso+™ device, a convenient, virtually pain-free blood lancet that collects whole liquid blood samples. The CE Mark designation allows Tasso to offer its patient-centric, high-volume blood collection solution in the European Union (EU) market, which includes 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements.

Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today announced that the TassoOne™ Plus, a new high-volume liquid blood collection device, has received CE Mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation. With this CE Mark, Tasso now expands its capabilities to offer patient-centric, high-volume blood collection solutions for the European market.

Tasso, Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+™ lancet as a Class II medical device. The clearance allows the company to market and sell the device to more pharmaceutical companies, healthcare organizations, and academic institutions across the country, expanding access to a simple and virtually painless blood collection experience.

Tasso, Inc., a leader in clinical-grade blood collection solutions, today announced the launch of Tasso PopPK Solutions, an integrated patient-centric offering for population pharmacokinetics (PopPK). With the launch of Tasso PopPK Solutions, Tasso now enables pharmaceutical companies to operationalize pharmacokinetic studies as part of their decentralized clinical trial efforts. Tasso's remote solution supports the scalable and convenient acquisition of pharmacokinetic data, improving modeling accuracy and accelerating clinical trials.

Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million. The financing round was led by RA Capital Management and included participation from new investors the D.E. Shaw group, Senvest, InCube, and SVB Innovation Fund, as well as existing investors Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai, and Merck GHIF.